Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

NCT04843774 · clinicaltrials.gov ↗

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: SARS-COV-2 mRNA Vaccine

Sponsor

NYU Langone Health